by Elena Iemma | Jun 23, 2026 | News
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded...
by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Oct 22, 2025 | Blog
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation If you know us, you know we love Tregs. Regulatory T cells (Tregs) are central to how we think about the immune system and nearly everything we do at EpiVax. So, we were thrilled to see this...
by Elena Iemma | Aug 19, 2025 | Blog
The Tregs as Medicine Symposium September 26, 2025 | The Westin Hotel, Meguro Tokyo The Tregs as Medicine: Tolerance and InTolerance Symposium will bring together leading scientists and clinicians to examine how regulatory T cells (Tregs) and tolerance...
by Elena Iemma | Jul 29, 2025 | Blog
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
